Hua Medicine is developing potentially disease-modifying therapeutics for type 2 diabetes, driven by mechanisms in the glucose homeostasis process. Having launched dorzagliatin in China in 2022, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback